PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
PDS Biotechnology Corporation reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price rule. Nasdaq had previously notified the company that its common stock closed below the required $1.00 per share for 30 consecutive business days, triggering a deficiency notice. On June 2, 2026, Nasdaq informed PDS Biotechnology that the company once again meets the Minimum Bid Price Requirement and that the compliance matter is now closed.
Positive
- None.
Negative
- None.
Insights
Regaining Nasdaq bid-price compliance removes immediate delisting risk.
PDS Biotechnology Corporation had fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, which led to a deficiency notice from the Nasdaq Listing Qualifications Department. Such notices can ultimately lead to delisting if not cured.
Nasdaq’s written confirmation on June 2, 2026 that the company now satisfies the Minimum Bid Price Requirement and has closed the matter means the stock currently retains its Nasdaq Capital Market listing under that rule. Actual long-term impact will depend on the company’s ability to maintain compliance as trading continues.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Minimum bid price threshold: $1.00 per share
Deficiency notice date: February 25, 2026
Compliance regained date: June 2, 2026
3 metrics
Minimum bid price threshold
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement
Deficiency notice date
February 25, 2026
Date Nasdaq notified PDS Biotechnology of non-compliance
Compliance regained date
June 2, 2026
Date Nasdaq confirmed PDS Biotechnology met bid price rule
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, Nasdaq Listing Qualifications Department
3 terms
Minimum Bid Price Requirement regulatory
"has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)."
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Nasdaq Listing Qualifications Department regulatory
"received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC"
The Nasdaq Listing Qualifications Department is the team at the Nasdaq stock market that monitors whether listed companies meet the exchange’s rules for things like minimum share price, market value, timely financial reporting and governance. Its role matters to investors because its notices, warnings or enforcement actions—ranging from reminders to suspension or delisting—can sharply affect a stock’s trading, liquidity and perceived risk; think of it as the referee enforcing the marketplace’s entry and conduct rules.
FAQ
What did PDS Biotechnology Corporation (PDSB) announce in this 8-K?
PDS Biotechnology announced it has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq confirmed the company now meets the listing requirement and has closed the prior deficiency matter related to the stock trading below the required threshold.
Why was PDS Biotechnology (PDSB) previously non-compliant with Nasdaq rules?
PDS Biotechnology became non-compliant because its common stock’s closing bid price was below $1.00 per share for 30 consecutive business days. This violated Nasdaq Listing Rule 5550(a)(2), known as the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market.
When did PDS Biotechnology (PDSB) receive the original Nasdaq deficiency notice?
The company received the original Nasdaq deficiency letter on February 25, 2026. That letter informed PDS Biotechnology that its common stock had failed to meet the $1.00 minimum bid price for 30 consecutive business days required for continued listing on the Nasdaq Capital Market.
When did PDS Biotechnology (PDSB) regain compliance with the Nasdaq bid price rule?
PDS Biotechnology received written notice from Nasdaq on June 2, 2026 confirming it had regained compliance. Nasdaq stated that the company again meets the Minimum Bid Price Requirement and that the related compliance matter has been closed.
What is the Nasdaq Minimum Bid Price Requirement mentioned for PDSB?
The Minimum Bid Price Requirement is Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 per share closing bid price for a company’s common stock. PDS Biotechnology temporarily failed this standard but has since been notified that it is again in compliance.